



WWW.newallaneeting

# Joint International Conference

# **Promises** and **challenges** of developing **new drugs** in **oncology**

Chairman: Luca Gianni, Milan I

# July 4-5, 2019

Congress Centre Palazzo Stelline Corso Magenta, 61 – Milan Meeting room: Leonardo (ground floor)

Endorsements



"ASCO" is a registered trademark of the American Society of Clinical Oncology® Used with permission. This is not an ASCO sponsored event."

1/4/33



# PRADA Group

of Fondazione Gianni Bonadonna

## ••••••• SCIENTIFIC COMMITTEE, SCIENTIFIC SECRETARIAT, FACULTY ••••••••

#### **Scientific Committee**

# Hilary Calvert UCL Cancer Institute, London, UK - University of Newcastle upon Tyne Luca Gianni San Raffaele Hospital - Scientific Institute, Milan, Italy Lajos Pusztai Yale Cancer Center, New Haven, USA **Cristiana Sessa** Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland Giuseppe Viale University of Milan, European Institute of Oncology, Milan, Italy **Scientific Secretariat Giampaolo Bianchini** Fondazione Michelangelo, Milan, Italy **Angelica Fasolo** Fondazione Michelangelo, Milan, Italy Faculty John Bell Hospital Research Institute, Ottawa, ON, Canada Giampaolo Bianchini San Raffaele Hospital - Scientific Institute, Milan, Italy Chiara Bonini

Vita-Salute San Raffaele University - Scientific Institute San Raffaele IRCCS, Milan, Italy

#### • Paolo Comoglio Candiolo Cancer Institute-IRCCS, Turin, Italy

#### Alexander Drilon Memorial Sloan Kettering Cancer Center, New York, USA

 Astrid Kiermaier Roche, Basel, Switzerland

#### Ravi Majeti

Department of Medicine, Division of Hematology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA, USA

WAS T

#### • Stephen Pettitt Breast Cancer Now Toby Robins Research Centre - Institute of Cancer Research, London, UK

- Lajos Pusztai Yale Cancer Center, New Haven, CT, USA
- Antoni Ribas UCLA Medical Center, Los Angeles, CA, USA
- Ahmed Sawas Columbia University Medical Center, New York, USA
- Michele Teng QIMR Berghofer Medical Research Institute, Brisbane, Austalia

#### 

The growth of therapeutic opportunities for cancer patients is driven by the deep understanding of tumor molecular biology and the clinical implementation of formidable technologies such as next-generation sequencing. At the same time, the transformative potential of immunotherapy concurs in providing unprecedented opportunities and new challenges in cancer therapy.

A faculty of leading international experts has been invited to present and discuss the ongoing revolution in cancer therapy and shape the scenarios of what we should expect in the future from the most promising areas of research.

It is well known that tumour cells are dependent and sometimes addicted to specific molecular alterations. Until recently, targeted therapy was only registered by target identification restricted to a specific tumor histology. The current knowledge of the molecular pan-cancer landscape has prompted a conceptual shift and led to the design of trials based on the genomic alteration rather than the site of origin of the tumors (i.e. basket trials). This is resulted in the identification and commercialization of "agnostic" therapies irrespective of organ site and histology, as in the case of NTRK fusion-positive or mismatch repair deficient cancers. Other new promising therapeutic targets such as MET or RET will be discussed in this context as well as the evolving opportunities provided by liquid biopsy and ctDNA assessment for personalized medicine. The capability to characterize the molecular features of individual tumor has also brought to the development of novel anticancer compounds such as antibody-drug conjugates and personalized cancer vaccines.

Immunotherapy is no longer hope or promise, but a revolutionary opportunity to treat almost all cancer types. However, the unquestionable clinical benefit of immunotherapy is so far restricted to a minority of patients. During the conference, we will discuss how combinations might overcome resistance, the most promising therapeutic approaches beyond immune checkpoints, and the definition of promising biomarkers for treatment tailoring. The implementation of immunotherapy in the neoadjuvant setting as an efficient and powerful approach for drug development will also be discussed.


Finally, as in all past editions of the Conference, the Gianni Bondonna Prize for new drug development in oncology will be awarded to a young and talented clinical researcher.

#### Gianni Bonadonna Prize for New Drug Development in Oncology

On the occasion of the Joint International Conference on "Promises and challenges of developing new drugs in oncology" the Fondazione Gianni Bonadonna is proud to announce the "Gianni Bonadonna Prize for New Drug Development in Oncology", aimed to promoting and improving clinical research on the development of novel compounds. The prize of € 20.000,00 will be assigned for an original oncology clinical research project for the development of novel compounds and it is addressed to researchers up to 40 years of age.

#### Poster Presentation

Poster display on Thursday July 4<sup>th</sup> and Friday July 5<sup>th</sup>.



Day 1, Thursday, July 4 <sup>th</sup> 2019	
13.30 - 14.30	Registration & welcome coffee
14.30 - 14.40	Welcome
14.40 - 15.25	<u>MAIN LECTURES</u> Anti-CD47 as a new "immune checkpoint": present status and prospective Ravi Majeti (Stanford, CA, USA)
15.25 - 15.35	Discussion
15.35 - 16.20	<b>Cell therapy: challenges and strategies for targeting solid tumors</b> Chiara Bonini (Milan, I)
16.20 - 16.30	Discussion
16.30 - 17.30	Gianni Bonadonna Prize Presentations of the three selected projects Report of the 2017 awardee Nicola Fenderico (Utrecht, NL - Barcelona, ES)

Day 2, Friday, July 5 <sup>th</sup> 2019	
	IMMUNOTHERAPY
9.00 - 9.30	<b>Oncolytic viruses: promises and challenges</b> John C. Bell (Ottawa, ON, Canada)
9.30 - 10.10	<b>Combinations using checkpoint blockade as one means to address resistance</b> Antoni Ribas (Los Angeles, CA, USA)
10.10 - 10.40	Neoadjuvant immunotherapy for the treatment of high-risk resectable cancers: a paradigm shift? Michele Teng (Brisbane, Australia)
10.40 - 11.15	Biomarkers for precision immunotherapy: elusive hope or forthcoming reality? Giampaolo Bianchini (Milan, I)
11.15 - 11.30	Coffee break
	<u>NEW DRUGS</u>
11.30 - 12.00	ADCs: a tip of an iceberg Ahmed Sawas (New York, USA)
12.00 - 12.30	Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Stephen Pettitt (London, UK)
12.30 - 13.00	<b>MET oncogene in cancer: a coherent approach to targeted therapy</b> Paolo Comoglio (Turin, I)
13.00 - 14.00	Lunch
	BIG DATA
14:00 - 14:35	<b>Strategies to use big data for improving drug development</b> Astrid Kiermaier (Basel, CH)
	TARGET COME FIRST: AGNOSTIC REGISTRATIONS
14.35 - 15.10	Rank genomic alterations as targets for precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets Lajos Pusztai (New Haven, CT, USA)
15.10 - 15.40	NTRK fusion-positive and RET-alterated cancers Alexander Drilon (New York, USA)
15.40 - 16.30	Gianni Bonadonna Prize (The Award Ceremony)

# 

### **Conference Venue**

#### **Congress Centre Palazzo Stelline**

Corso Magenta, 61 – Milan Meeting room: Leonardo (ground floor) Underground: MM1/MM2 Cadorna, MM1 Conciliazione, MM2 S.Ambrogio Train: FNM Stazione Cadorna Tram: 16 - 19 Bus: 50 - 58 - 67 - 94

#### Dates of the Conference

#### From Thursday, July 4 to Friday, July 5 2019

\_\_\_\_\_

### **Official Language**

The official language of the Conference is English. No translation will be provided.

#### **Application**

Attendance is free of charge, however application is compulsory until June 28, 2019

# **CLICK HERE**

to submit your application

#### Accommodation

To require hotel accommodation in Milan, please fill in the registration form online; for further information, contact the Organizing Secretariat to <u>michelangelo@newaurameeting.it</u>

#### Acknowledgements

The Scientific Committee and Secretariat wish to thank the following Companies for their unrestricted support:



Scientific Secretariat • Giampaolo Bianchini • Angelica Fasolo Fondazione Michelangelo Via A. Bertani, 14 – 20154 Milano, Italy Phone +39 02 87086420 Fax +39 02 87086449 E-mail: segreteria@fondazionemichelangelo.org Organizing Secretariat New Aurameeting Srl Via Rocca d'Anfo, 7 – 20161 Milan, Italy Phone: +39 02 66203390 Fax: +39 02 66200418 E-mail: <u>michelangelo@newaurameeting.it</u> www.newaurameeting.it